To Evaluate Efficacy and Safety of Proprietary Healthy Diet Combinations for Weight Management in Overweight Volunteers
NCT07452757 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140
Last updated 2026-03-12
Summary
This is an open-label, four-arm, randomized, controlled clinical study designed to evaluate the efficacy and safety of a structured Weight Management Program (WMP) in overweight and obese adults with a body mass index (BMI) ≥ 23 kg/m² (Asian Indian ethnicity cut-off). A total of 140 subjects will be enrolled and randomized equally into four arms: one control arm and three intervention arms with varying levels of nutritional intervention.
The Weight Management Program comprises three sequential phases: a pre-engagement gut-reset phase (10 days), an intensive intervention phase (30 days), and a maintenance phase (60 days). The intervention arms will receive combinations of meal replacements, protein supplements, fiber supplements, probiotics, and multivitamin-multimineral supplements, along with nutritional and behavioral counseling, calorie-deficit diet plans, and prescribed physical activity. The control arm will follow a free-living lifestyle without intervention.
The primary efficacy outcome is the proportion of subjects demonstrating a reduction in body weight and/or BMI from baseline to the end of the intensive phase. Secondary outcomes include changes in body weight and BMI at the end of the maintenance phase, maintenance of weight loss, changes in body composition, waist circumference, waist-hip ratio, lipid profile, metabolic parameters, physical activity, quality of life, and safety outcomes including adverse events.
The study aims to generate evidence on the effectiveness and safety of a holistic, lifestyle-based weight management program incorporating nutritional supplementation, dietary modification, physical activity, and behavioral support in overweight and obese individuals.
Conditions
- Overweight (BMI > 25)
Interventions
- DIETARY_SUPPLEMENT
-
Arm II
I. Investigational Product Morning- PRP-02 (1 scoop) + AND-16 Afternoon- PRP-02 (1 scoop) Night-PRP-02 (1 scoop) + FBR-18 (1 scoop) +PRO-19 II. Nutritional+ Behavioral counselling (Audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60-minute exercise 5 days a week or 150-300-minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)
- DIETARY_SUPPLEMENT
-
Arm III
I. Investigational Product - Replace breakfast with BDK-01+PRP-02 (2 scoops) Afternoon - as per diet plan Night- FBR- 18 (1 scoop) +PRO- 19 II. Nutritional + Behavioral counselling (Daily audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60 minute exercise 5 days a week or 150 - 300 minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)
- DIETARY_SUPPLEMENT
-
Arm IV
I. Investigational Product Replace breakfast with BDK-01+PRP-02 (2 scoops) Afternoon-BDK-01+ Skimmed milk powder (Only during intensive phase, in maintenance phase switch to 1 meal replacement only) Night-FBR- 18+PRO- 19 II. Nutritional + Behavioral counselling (Daily audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60 minute exercise 5 days a week or 150-300 minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)
Sponsors & Collaborators
-
Bioagile Therapeutics Pvt. Ltd.
lead INDUSTRY
Principal Investigators
-
Divya Divya · BioAgile Therapeutics Private Limited
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-11-15
- Primary Completion
- 2024-05-13
- Completion
- 2024-05-13
Countries
- India
Study Locations
More Related Trials
-
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
NCT04667377 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Patients Being Treated With Anti-obesity Medication
NCT06790160 ·Status: RECRUITING
-
Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial
NCT07103382 ·Status: RECRUITING ·Phase: NA
-
Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers
NCT00479492 ·Status: COMPLETED ·Phase: PHASE2
-
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing
NCT06820476 ·Status: COMPLETED ·Phase: PHASE1
-
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
NCT00747929 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of IQP-VV-102 in Weight Management
NCT01681069 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
NCT07166081 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
NCT05677867 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
NCT06717425 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
NCT01905956 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 1 Study of NGM313 in Healthy Adult Participants
NCT02708576 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity
NCT01970566 ·Status: WITHDRAWN ·Phase: NA
-
Benefit and Tolerability of IQP-LU-104 in Weight Loss
NCT03888911 ·Status: COMPLETED ·Phase: NA
-
A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight
NCT04447261 ·Status: COMPLETED ·Phase: PHASE1
-
Benefit and Tolerability of IQP-AE-103 in Weight Loss
NCT03058367 ·Status: COMPLETED ·Phase: NA
-
Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
NCT07245771 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of ZT006 in Overweight and Obese Participants
NCT07230132 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion
NCT07097987 ·Status: COMPLETED ·Phase: NA
-
The Effects of the GOLO for Life® Plan and Release Supplement on Weight Management in Overweight and Obese Adults
NCT05844631 ·Status: COMPLETED ·Phase: PHASE2
-
DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects
NCT04086797 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of IBI362 in Healthy Chinese Male Subjects
NCT04773977 ·Status: COMPLETED ·Phase: PHASE1
-
β-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity Adults
NCT04953936 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
NCT04707313 ·Status: COMPLETED ·Phase: PHASE2